Skip to content

Study · Observational study · 2026

7 results

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Michalak W, Bøg M, Bendixen T, Chowdhury R, Cowley P, Laugesen C, Rathor N, Kushner RF

Diabetes, obesity & metabolism1 Jun 2026Cited by 2 (Europe PMC)

PMID42225305 (opens in a new tab)PMCIDPMC13341387 (opens in a new tab)DOI10.1111/dom.70919 (opens in a new tab)PepBankPUB-42225305
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with overweight or obesity without diabetes, orforglipron produced less weight loss than oral semaglutide in the treatment-regimen analysis.

    In plain wordsIn adults without diabetes, orforglipron produced less weight loss than oral semaglutide in the treatment-regimen analysis.

    Peptide
    Orforglipron
    Outcome
    IncreaseWeight change, treatment-regimen estimand
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    36 mg · oralAs given in this study (human).

    Measurements

    Mean difference in body weight change (oral semaglutide 25 mg vs orforglipron 36 mg)
    −3.2 %-points
    treatment-regimen estimand
    95% CI of mean difference
    −5.9 to −0.4 %-points
    treatment-regimen estimand

    Source sentences

    Summary
    Population-adjusted analyses showed a significantly greater percentage change from baseline in body weight with oral semaglutide 25 mg than with orforglipron 36 mg, with mean differences (MDs) of -3.2%-points (95% confidence intervals [CIs]: -5.9, -0.4; treatment-regimen estimand) and -3.0%-points (…
    2 context sentences
    Summary · context
    Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).
    Summary · context
    Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.
  2. 02HumanObservational studyEfficacy outcome

    In adults with overweight or obesity without diabetes, orforglipron produced less weight loss than oral semaglutide in the efficacy analysis.

    In plain wordsIn adults without diabetes, orforglipron produced less weight loss than oral semaglutide in the efficacy analysis.

    Peptide
    Orforglipron
    Outcome
    IncreaseWeight change, efficacy estimand
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    36 mg · oralAs given in this study (human).

    Measurements

    Mean difference in body weight change (oral semaglutide 25 mg vs orforglipron 36 mg)
    −3 %-points
    efficacy estimand
    95% CI of mean difference
    −5.8 to −0.3 %-points
    efficacy estimand

    Source sentences

    Summary
    Population-adjusted analyses showed a significantly greater percentage change from baseline in body weight with oral semaglutide 25 mg than with orforglipron 36 mg, with mean differences (MDs) of -3.2%-points (95% confidence intervals [CIs]: -5.9, -0.4; treatment-regimen estimand) and -3.0%-points (…
    2 context sentences
    Summary · context
    Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).
    Summary · context
    Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.
  3. 03HumanObservational studySafety outcome

    In adults without diabetes, adverse-event discontinuation was higher with orforglipron than oral semaglutide, with an odds ratio of 4.1.

    In plain wordsIn adults without diabetes, adverse-event discontinuation was higher with orforglipron than oral semaglutide.

    Peptide
    Orforglipron
    Outcome
    IncreaseDiscontinuation due to any adverse event
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg
    Outcome group
    Adverse events · Whole body
    Studied dose
    36 mg · oralAs given in this study (human).

    Measurements

    Odds ratio, discontinuation due to any adverse event (orforglipron 36 mg vs oral semaglutide 25 mg)
    4.1 odds ratio
    any AE
    95% CI of odds ratio
    1.3 to 13 odds ratio
    any AE

    Source sentences

    Summary
    Discontinuation was higher with orforglipron (due to any AE: odds ratio [OR]: 4.1 [95% CI: 1.3, 13.0] and due to GI AEs: OR: 13.9 [95% CI: 2.0, 96.0]).
    2 context sentences
    Summary · context
    Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).
    Summary · context
    Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.
  4. 04HumanObservational studySafety outcome

    In adults without diabetes, gastrointestinal-event discontinuation was higher with orforglipron than oral semaglutide, with an odds ratio of 13.9.

    In plain wordsIn adults without diabetes, gastrointestinal-event discontinuation was higher with orforglipron than oral semaglutide.

    Peptide
    Orforglipron
    Outcome
    IncreaseDiscontinuation due to gastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    36 mg · oralAs given in this study (human).

    Measurements

    Odds ratio, discontinuation due to gastrointestinal adverse events (orforglipron 36 mg vs oral semaglutide 25 mg)
    13.9 odds ratio
    GI AEs
    95% CI of odds ratio
    2 to 96 odds ratio
    GI AEs

    Source sentences

    Summary
    Discontinuation was higher with orforglipron (due to any AE: odds ratio [OR]: 4.1 [95% CI: 1.3, 13.0] and due to GI AEs: OR: 13.9 [95% CI: 2.0, 96.0]).
    2 context sentences
    Summary · context
    Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).
    Summary · context
    Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.
  5. 05HumanOther designEfficacy outcome

    In adults with overweight or obesity without diabetes, an indirect comparison found a significantly greater percentage body weight loss with oral semaglutide 25 mg than with orforglipron 36 mg (mean difference -3.2 percentage points, treatment-regimen estimand).

    In plain wordsIn adults with overweight or obesity without diabetes, oral semaglutide led to more weight loss than orforglipron in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage change in body weight, oral semaglutide versus orforglipron
    Study

    n: not reported in source

    Comparator
    Orforglipron 36 mg (indirect)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    25 mg · oralAs given in this study (human).

    Measurements

    Mean difference, treatment-regimen estimand
    −3.2 %-points
    semaglutide versus orforglipron
    Mean difference, efficacy estimand
    −3 %-points
    semaglutide versus orforglipron

    Source sentences

    Summary
    Population-adjusted analyses showed a significantly greater percentage change from baseline in body weight with oral semaglutide 25 mg than with orforglipron 36 mg, with mean differences (MDs) of -3.2%-points (95% confidence intervals [CIs]: -5.9, -0.4; treatment-regimen estimand) and -3.0%-points (…
    2 context sentences
    Summary · context
    Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).
    Summary · context
    Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.
  6. 06HumanOther designSafety outcome

    In adults with overweight or obesity without diabetes, discontinuation due to any adverse event was higher with orforglipron than with oral semaglutide (OR 4.1, 95% CI 1.3 to 13.0), so lower with semaglutide in this indirect comparison.

    In plain wordsIn adults with overweight or obesity without diabetes, fewer people stopped oral semaglutide because of side effects than stopped orforglipron, in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiscontinuation due to any adverse event
    Study

    n: not reported in source

    Comparator
    Orforglipron 36 mg (indirect)
    Outcome group
    Adverse events · Whole body
    Studied dose
    25 mg · oralAs given in this study (human).

    Measurements

    OR for discontinuation, orforglipron versus semaglutide
    4.1 OR
    any adverse event

    Source sentences

    Summary
    Discontinuation was higher with orforglipron (due to any AE: odds ratio [OR]: 4.1 [95% CI: 1.3, 13.0] and due to GI AEs: OR: 13.9 [95% CI: 2.0, 96.0]).
    2 context sentences
    Summary · context
    Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).
    Summary · context
    Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.
  7. 07HumanOther designSafety outcome

    In adults with overweight or obesity without diabetes, discontinuation due to gastrointestinal adverse events was higher with orforglipron than with oral semaglutide (OR 13.9, 95% CI 2.0 to 96.0), so lower with semaglutide in this indirect comparison.

    In plain wordsIn adults with overweight or obesity, fewer people stopped oral semaglutide than orforglipron because of stomach and gut side effects, in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiscontinuation due to gastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Orforglipron 36 mg (indirect)
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    25 mg · oralAs given in this study (human).

    Measurements

    OR for discontinuation, orforglipron versus semaglutide
    13.9 OR
    gastrointestinal adverse events

    Source sentences

    Summary
    Discontinuation was higher with orforglipron (due to any AE: odds ratio [OR]: 4.1 [95% CI: 1.3, 13.0] and due to GI AEs: OR: 13.9 [95% CI: 2.0, 96.0]).
    2 context sentences
    Summary · context
    Individual patient data from OASIS 4 and aggregate data from ATTAIN-1 informed anchored indirect treatment comparisons (ITCs).
    Summary · context
    Baseline differences in sex, body weight and normoglycaemic status were adjusted for using population-adjustment methods.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 15Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 12 times, first on 14 Oct 2026, 05:02 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    11 Oct 2026, 00:04 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.